Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long-term study.

ABSTRACT:

Background

Pulmonary arterial hypertension (PAH) is a progressive disease with limited survival. Iron deficiency (ID) correlates with disease severity and mortality. While oral iron supplementation was shown to be insufficient in such patients, the potential impact of parenteral iron on clinical measures warrants further investigation.

Methods

We retrospectively analysed the long-term effects of intravenous ferric carboxymaltose (FCM) on iron status and clinical measures in patients with PAH and ID [ferritin < 100 μg/L or ferritin 100-300 μg/L and transferrin saturation (TSAT) < 20%] who were on stable targeted PAH therapy, compared with matched controls without ID. Patients with ID received a single infusion of FCM (500 to 1000 mg). Clinical measures monitored included exer

SUBMITTER: Kramer T 

PROVIDER: S-EPMC8718050 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature